House, Senate Differ In Treating FDA China Syndrome
This article was originally published in The Tan Sheet
Executive Summary
Appropriators in the House and Senate endorse FDA’s plan to spend $10 million more on inspections in China in 2013, but only the Senate approves increasing the agency’s budget to cover the costs. FDA’s request for China inspections includes $5.6 million for inspections at drug facilities.
You may also be interested in...
Congress Instructs FDA On Nanotech Work, But Mum On Regulations
The recently passed user fee reauthorization includes a provision that directs FDA to evaluate nano-engineered products’ potential benefits and safety. Friends of the Earth says nanotech products are available “prematurely … without having enough safety data.”
Congress Instructs FDA On Nanotech Work, But Mum On Regulations
The recently passed user fee reauthorization includes a provision that directs FDA to evaluate nano-engineered products’ potential benefits and safety. Friends of the Earth says nanotech products are available “prematurely … without having enough safety data.”
Congress Instructs FDA On Nanotech Work, But Mute On Funding
Newly passed user-fee legislation includes a provision directing FDA to intensify its research and policy development regarding nanotechnology and its use in consumer products. How such efforts are to be funded remains a question.